Prairie Capital partnered with founder Dr. Zahra Kashi and senior management to recapitalize Kashi Clinical Laboratories (“Kashi” or the “Company”). Headquartered in Portland, OR, Kashi Clinical Laboratories is a fully accredited clinical laboratory providing specialized solutions to academic institutions, biopharma, hospitals, long-term care facilities and transplant centers around the world.

The Company was founded in 2006 to provide high-resolution HLA typing for transplant donor matching. Over time, Kashi expanded its service offering to include post-transplant monitoring, genomic sequencing and other diagnostic testing. Kashi enjoys industry-leading customer satisfaction and is renowned for its rapid turnaround time, scientific expertise, customer service and innovation using state-of-the-art technology.

Kashi’s aggregate market opportunity exceeds $20 billion, and demand for Kashi’s lab offerings is robust. Transplant volume is growing due to an aging population, increased prevalence of cancer / acute diseases, dietary habits and other factors. Kashi’s full suite of lab services provide customers with critical pre-transplant matching and precise post-transplant monitoring. In addition, biotech and pharmaceutical organizations spend more than $250 billion per year researching and developing therapeutics, the services for which are routinely outsourced to independent labs. Kashi’s ability to provide accurate and timely HLA-typing in addition to a variety of complementary tests provides a unique service offering to numerous organizations.

Prairie partnered with the founder and senior management to accelerate the growth of Kashi through company-building investments in human capital, sales & marketing, technology, infrastructure, new services and add-on acquisitions.

For more information on Kashi Clinical Laboratories and/or any add-on acquisition opportunities, please contact:

Michael Praljak at mpraljak@prairie-capital.com
Sean McNally at smcnally@prairie-capital.com